Teva Stabilizes North American Generics Sales

 
• By Aidan Fry

Teva says optimizing its portfolio and recent launches have brought stability to its North American generics business. But problems persist elsewhere within the Israeli group, leading it to post a $644m operating loss in the second quarter.

Law_Books
Teva says its North American generics operation has stabilized, but the threat of US opioids litigation still hangs over the company • Source: Shutterstock

More from Earnings

More from Business